Pulmonx Corp.
- LUNG · Nasdaq
- Surgical & Medical Instruments & Apparatus
- Redwood City, CA
- 296 employees
- CIK 0001127537
Updated from SEC filings through
Top things to know
Executives
- Glen French President and Chief Executive Officer of Pulmonx 8-K, 2026-10-27
- Glendon E. French III President and CEO 4, 2026-09-03
-
Derrick Sung Chief Operating Officer and Chief Financial Officer 10-K, 2026-03-10 - Geoffrey Beran Rose Chief Commercial Officer 4, 2026-09-03
- Srikanth Radhakrishnan Chief Science & Techn. Officer 4, 2026-09-03
- David Aaron Lehman General Counsel 4, 2026-09-03
What leadership is saying
“We are very pleased to have returned to year-over-year revenue growth in the third quarter. We continue to execute on our commercial strategy, advance our clinical initiatives, and deliver the operating leverage we expected”
Earnings press release (8-K Ex. 99.1), filed October 27, 2026
Pulmonx Corp is a U.S. public company in surgical & medical instruments & apparatus (SIC 3841), headquartered in Redwood City, CA. It trades as LUNG on Nasdaq. Revenue was $90.5M in the fiscal year ending December 31, 2025, +8.0% from the year before. It reported about 296 employees. Glen French is President and Chief Executive Officer of Pulmonx.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $90.5M 10-K, 2026-03-10 | $83.8M 10-K, 2026-03-10 | $68.7M 10-K, 2025-02-25 | $53.7M 10-K, 2024-02-27 | $48.4M 10-K, 2023-03-01 |
| Operating income | -$53.7M 10-K, 2026-03-10 | -$57.7M 10-K, 2026-03-10 | -$61.9M 10-K, 2025-02-25 | -$58.6M 10-K, 2024-02-27 | -$47.3M 10-K, 2023-03-01 |
| SG&A | $101M 10-K, 2026-03-10 | $102M 10-K, 2026-03-10 | $94.6M 10-K, 2025-02-25 | $83.1M 10-K, 2024-02-27 | $69.9M 10-K, 2023-03-01 |
| Net income | -$54.0M 10-K, 2026-03-10 | -$56.4M 10-K, 2026-03-10 | -$60.8M 10-K, 2025-02-25 | -$58.9M 10-K, 2024-02-27 | -$48.7M 10-K, 2023-03-01 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Glen French Medical Device Executive, Board Member, and Advisor | President and Chief Executive Officer of Pulmonx | 8-K, 2026-10-27 |
| Glendon E. French III | President and CEO | 4, 2026-09-03 |
| Derrick Sung Chief Operating Officer & Chief Financial Officer at Pulmonx Corporation | Chief Operating Officer and Chief Financial Officer | 10-K, 2026-03-10 |
| Geoffrey Beran Rose | Chief Commercial Officer | 4, 2026-09-03 |
| Srikanth Radhakrishnan | Chief Science & Techn. Officer | 4, 2026-09-03 |
| David Aaron Lehman | General Counsel | 4, 2026-09-03 |
| David Lehman | Named in proxy bio: General Counsel | DEF 14A, 2026-04-22 |
| Dana G. Mead, Jr. | Director | 10-K, 2026-03-10 |
| Daniel P. Florin | Director | 10-K, 2026-03-10 |
| Georgia Garinois-Melenikiotou | Director | 10-K, 2026-03-10 |
| Richard Ferrari | Director | 10-K, 2026-03-10 |
| Thomas W. Burns | Director | 10-K, 2026-03-10 |
| Tiffany Sullivan | Director | 10-K, 2026-03-10 |
What Pulmonx Corp does
We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). Our solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 43.6 million (as of October 29, 2026) | 10-Q, November 3, 2026 |
|---|---|---|
| Public float | $101M (as of June 30, 2025) | 10-K, March 10, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 3, 2026 |
| Latest proxy statement | Meeting June 4, 2026 (filed April 22, 2026) | DEF 14A, April 22, 2026 |
| Auditor | Bdo Usa, P.c. (San Francisco, California) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 1, 2026 | Srikanth Radhakrishnan Chief Science & Techn. Officer | Sale | 14,245 | $32K | Form 4, September 3, 2026 |
| September 1, 2026 | Glendon E. French III President and CEO | Sale | 41,882 | $95K | Form 4, September 3, 2026 |
| September 1, 2026 | Geoffrey Beran Rose Chief Commercial Officer | Sale | 7,879 | $18K | Form 4, September 3, 2026 |
| September 1, 2026 | David Aaron Lehman General Counsel | Sale | 14,334 | $32K | Form 4, September 3, 2026 |
| June 2, 2026 | Glendon E. French III President and CEO | Sale | 56,149 | $87K | Form 4, June 3, 2026 |
| June 1, 2026 | Srikanth Radhakrishnan Chief Science &Techn. Officer | Sale | 14,497 | $22K | Form 4, June 3, 2026 |
| June 1, 2026 | Geoffrey Beran Rose CHIEF COMMERCIAL OFFICER | Sale | 8,023 | $12K | Form 4, June 3, 2026 |
| June 1, 2026 | David Aaron Lehman GENERAL COUNSEL | Sale | 14,594 | $22K | Form 4, June 3, 2026 |
Recent 8-K events
- 8-K filed 2026-10-27
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-04
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-04-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-05
- Item 1.01 Entry into a material definitive agreement
- Item 1.02 Termination of a material definitive agreement
- Item 2.03 Creation of a direct financial obligation
- Item 3.02 Unregistered sales of equity securities
- 8-K filed 2026-03-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-10-27
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2025-07-30
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-05-23
- Item 5.07 Submission of matters to a vote of security holders
Frequently asked questions about Pulmonx Corp
- What does Pulmonx Corp do?
- In its own words, from Item 1 of its 10-K: "We are a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (“COPD”). Our solution, which is comprised of the Zephyr Endobronchial Valve (“Zephyr Valve”), the Chartis Pulmonary Assessment System (“Chartis System”) and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches."
- What is Pulmonx Corp's revenue?
- $90.5M for the fiscal year ending December 31, 2025, from its 10-K filed March 10, 2026.
- Is Pulmonx Corp profitable?
- Pulmonx Corp reported net income of -$54.0M for the fiscal year ending December 31, 2025.
- How many employees does Pulmonx Corp have?
- About 296 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Pulmonx Corp?
- Glen French, President and Chief Executive Officer of Pulmonx, as named in a 8-K filed October 27, 2026.
- Who is the CFO of Pulmonx Corp?
- Derrick Sung, Chief Operating Officer and Chief Financial Officer, as named in a 10-K filed March 10, 2026.
- Where is Pulmonx Corp headquartered?
- Redwood City, CA.
- What is Pulmonx Corp's stock ticker?
- LUNG on Nasdaq.
- What industry is Pulmonx Corp in?
- Surgical & Medical Instruments & Apparatus, SIC code 3841.
- What is Pulmonx Corp's website?
- pulmonx.com.
- When does Pulmonx Corp report earnings next?
- November 11, 2026. Source: pg_earnings_events.
- Is Pulmonx Corp a public company?
- Yes. Pulmonx Corp files with the SEC under CIK 0001127537 and trades as LUNG.
- Who audits Pulmonx Corp?
- Bdo Usa, P.c., San Francisco, California, as named in its latest annual report (10-K).
- How many shares of Pulmonx Corp are outstanding?
- 43.6 million shares as of October 29, 2026, from its 10-Q filed November 3, 2026.
- What is Pulmonx Corp's public float?
- $101M as of June 30, 2025, as reported on the cover of its 10-K filed March 10, 2026.
- How many business segments does Pulmonx Corp report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 3, 2026.
- When is Pulmonx Corp's annual shareholder meeting?
- June 4, 2026, per its proxy statement (DEF 14A) filed April 22, 2026.
- Have Pulmonx Corp insiders traded stock recently?
- Since September 2, 2025, officers and directors reported 20 open-market sales worth about $602K and 0 purchases on Forms 4 and 5. The most recent: Srikanth Radhakrishnan (Chief Science & Techn. Officer) sold 14,245 shares on September 1, 2026.